Detalles de la búsqueda
1.
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
Lancet Oncol
; 21(6): 763-775, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32353342
2.
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial.
Lancet Oncol
; 21(10): 1296-1308, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32919527
3.
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.
Lancet
; 393(10191): 2599-2612, 2019 06 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-31178152
4.
Health-related quality of life and work productivity in UK patients with HER2-positive breast cancer: a cross-sectional study evaluating the relationships between disease and treatment stage.
Health Qual Life Outcomes
; 18(1): 353, 2020 Nov 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33138835
5.
Adjuvant trastuzumab duration trials in HER2 positive breast cancer - what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results.
BMC Cancer
; 18(1): 391, 2018 04 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29621991
6.
Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial.
Lancet Oncol
; 18(6): 755-769, 2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28479233
7.
Patient-derived Mammosphere and Xenograft Tumour Initiation Correlates with Progression to Metastasis.
J Mammary Gland Biol Neoplasia
; 21(3-4): 99-109, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27680982
8.
Protective strategies to prevent trastuzumab-induced cardiotoxicity - Authors' reply.
Lancet
; 395(10223): 492-493, 2020 02 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32061290
9.
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial.
Lancet Oncol
; 14(10): 989-98, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23902874
10.
Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study.
NPJ Breast Cancer
; 9(1): 81, 2023 Oct 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37803017
11.
Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010).
Clin Cancer Res
; 29(23): 4751-4759, 2023 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37773077
12.
Erratum to: Patient-Derived Mammosphere and Xenograft Tumour Initiation Correlates with Progression to Metastasis.
J Mammary Gland Biol Neoplasia
; 21(3-4): 111, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27815673
13.
A randomised, pragmatic clinical trial of ACUpuncture plus standard care versus standard care alone FOr Chemotherapy Induced peripheral Neuropathy (ACUFOCIN).
Eur J Oncol Nurs
; 60: 102171, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-35952460
14.
Facilitating reproductive choices: the impact of health services on the experiences of young women with breast cancer.
Psychooncology
; 20(10): 1044-52, 2011 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-20818600
15.
Genomic profile of advanced breast cancer in circulating tumour DNA.
Nat Commun
; 12(1): 2423, 2021 04 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-33893289
16.
Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer.
Breast Cancer Res Treat
; 120(2): 461-7, 2010 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-20107891
17.
Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT.
Health Technol Assess
; 24(40): 1-190, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32880572
18.
A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO).
Clin Cancer Res
; 25(9): 2717-2724, 2019 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30563931
19.
A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy.
Breast Cancer Res Treat
; 110(2): 327-35, 2008 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-17851757
20.
Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
Adv Ther
; 25(12): 1257-75, 2008 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-19096768